In the remaining five patients, standard therapy was unclear due to the lack of information on HER2 and/or hormone receptor status (in three patients with DCIS, standard systemic therapy was considered as hormone therapy although information on HER2 status was lacking). The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.